Autologous Hematopoietic Stem Cell Transplantation for Autoimmune Disease-Is It Now Ready for PrimeTime?

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 1 SUPPL., 2012, Pages

  Atkins, Harold L ^a   Muraro, Paolo A ^b   van Laar, Jacob M ^c   Pavletic, Steven Z ^d  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Autoimmune disease; Hematopoietic stem cell transplantation; Multiple sclerosis; Systemic sclerosis

Indexed keywords

BETA INTERFERON; BUSULFAN; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLATIRAMER; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; STEROID; THYMOCYTE ANTIBODY;

ARTICLE; ARTIFICIAL HEART PACEMAKER; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CACHEXIA; CD34 SELECTION; DISEASE COURSE; DISEASE SEVERITY; FEBRILE NEUTROPENIA; FOLLOW UP; HEMATOPOIETIC STEM CELL; HEMORRHAGIC CYSTITIS; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOCOMPETENT CELL; MULTIPLE SCLEROSIS; MYOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT SELECTION; PHYSIOTHERAPY; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SALVAGE THERAPY; SCLERODERMA; SMOKING CESSATION; SYSTEMIC SCLEROSIS; URINARY TRACT INFECTION; WHOLE BODY RADIATION;

AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84855378324     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.11.020     Document Type: Article

References (30)

1. Sullivan K.M., Muraro P., Tyndall A. Hematopoietic cell transplantation for autoimmune disease: updates from Europe and the United States. Biol Blood Marrow Transplant 2010, (1 Suppl):S48-S56.
2. Farge D., Labopin M., Tyndall A., et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica 2010, 95:284-292.
3. Pavletic S.Z. HSCT for AID: entering prime time?. Blood 2011, 118:1438-1439.
4. Singh J.A., Wells G.A., Christensen R., et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011, 2:CD008794.
5. Muraro P.A., Cassiani Ingoni R., Martin R. Hematopoietic stem cell transplantation for multiple sclerosis: current status and future challenges. Curr Opin Neurol 2003, 16:299-305.
6. Muraro P.A., Douek D.C., Packer A., et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 2005, 201:805-816.
7. Mancardi G., Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol 2008, 7:626-636.
8. Mancardi G.L., Saccardi R., Filippi M., et al. Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology 2001, 57:62-68.
9. Saiz A., Carreras E., Berenguer J., et al. MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS. Neurology 2001, 56:1084-1089.
10. Saccardi R., Mancardi G.L., Solari A., et al. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood 2005, 105:2601-2607.
11. Saccardi R., Kozak T., Bocelli-Tyndall C., et al. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler 2006, 12:814-823.
12. Krasulova E., Trneny M., Kozak T., et al. High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience. Mult Scler 2010, 16:685-693.
13. Saiz A., Blanco Y., Berenguer J., et al. [Clinical outcome 6 years after autologous hematopoietic stem cell transplantation in multiple sclerosis]. Neurologia 2008, 23:405-407.
14. Burt R.K., Cohen B.A., Russell E., et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of atotal body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood 2003, 102:2373-2378.
15. Nash R.A., Bowen J.D., McSweeney P.A., et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 2003, 102:2364-2372.
16. Burt R.K., Loh Y., Cohen B., et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet. Neurol 2009, 8:244-253.
17. Shevchenko Y.L., Novik A.A., Kuznetsov A.N., et al. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis. Exp Hematol 2008, 36:922-928.
18. Fagius J., Lundgren J., Oberg G. Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation. Mult Scler 2009, 15:229-237.
19. Kimiskidis V., Sakellari I., Tsimourtou V., et al. Autologous stem-cell transplantation in malignant multiple sclerosis:a case with a favorable long-term outcome. Mult Scler 2008, 14:278-283.
20. Portaccio E., Amato M.P., Siracusa G., et al. Autologous hematopoietic stem cell transplantation for very active relapsing-remitting multiple sclerosis: report of two cases. Mult Scler 2007, 13:676-678.
21. Center for International Blood and Marrow Transplant Research Website (last accessed September 15, 2011). Available at: http://www.cibmtr.org/DataManagement/DataCollectionForms/Documents/2043/Rev2.0/combine-2043%20MS%20v2.pdf.
22. Openshaw H., Stuve O., Antel J.P., et al. Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor. Neurology 2000, 54:2147-2150.
23. Atkins H., Freedman M. Immune ablation followed by autologous hematopoietic stem cell transplantation for the treatment of poor prognosis multiple sclerosis. Methods Mol Biol 2009, 549:231-246.
24. Hamerschlak N., Rodrigues M., Moraes D.A., et al. Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG. Bone Marrow Transplant 2010, 45:239-248.
25. Nash R.A., Dansey R., Storek J., et al. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol Blood Marrow Transplant 2003, 9:583-591.
26. Daikeler T., Labopin M., Di Gioia M., et al. Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. Blood 2011, 118:1693-1698.
27. Binks M., Passweg J.R., Furst D., McSweeney P., Sullivan K., Besenthal C., et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001, 60:577-584.
28. Nash R.A., McSweeney P.A., Crofford L.J., Abidi M., Chen C.S., Godwin J.D., et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 2007, 110:1388-1396.
29. Vonk M.C., Marjanovic Z., van den Hoogen F.H., Zohar S., Schattenberg A.V., Fibbe W.E., et al. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis 2008, 67:98-104.
30. Burt R.K., Shah S.J., Dill K., Grant T., Gheorghiade M., Schroeder J., et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011, 378:498-506.